Developer docs
API playgroundTry for free, no card

Search company profiles

Sigachi

Full company profile

uuid0008o98

Namestring
Sigachi
Legal namestring
Sigachi Industries Limited
Websiteurl
sigachi.com
Company typeenum
Public
Founded yearint
1989
Descriptiontext

Sigachi Industries Limited, founded in 1989 in Hyderabad and publicly listed on BSE/NSE since 2021 (ticker: SIGACHI), is a vertically integrated Indian manufacturer of pharmaceutical excipients, Active Pharmaceutical Ingredients (APIs), food and nutrition additives, and cosmetic ingredients, with a parallel Operations & Maintenance (O&M) services line for chemical, petrochemical, fertilizer, and energy plants. Its core technical platform centres on Microcrystalline Cellulose (MCC) manufacturing — branded as HiCel™ (spray-dried directly compressible grades) and AceCel® (non-spray-dried grades for wet granulation) — extended into co-processed excipients (BARETab® PH/ODT/Nutra, HiCel™ HFS/CE15/SMCC), ready-mix film coatings (PureCoat®), sustained-release polymer blends (UltraMod™ SR), superdisintegrants (Stargel®, HiLose™), and lubricants (MagLub®, FloLub™). Two DSIR-accredited R&D centres support new molecule development, and the company runs five manufacturing facilities across Telangana, Gujarat, and Karnataka with combined capacity of 21,700 MTPA.

The business model is sales-led B2B, selling through direct enterprise sales teams in India, wholly-owned subsidiaries Sigachi US Inc. and Sigachi MENA FZCO in the Americas and Middle East, and channel partners across 65+ countries; approximately 60% of output is exported into highly regulated markets (US, Europe, Australia) where USFDA, EDQM CEP, EXCiPACT GMP, WHO-GMP, HACCP, ISO 9001/14001/45001 certifications act as entry barriers. Pricing is quote-based and negotiated under multi-year contracts. Revenue is generated across four streams: pharmaceutical excipients (the core, including binders, disintegrants, coatings, lubricants, carriers), APIs (9 products including Pregabalin, Ritonavir, Metformin, Atorvastatin — 15% of revenue after the August 2023 acquisition of 80% of Trimax Bio Sciences for Rs 100 crore), food/nutrition premixes (Joymix®, AceFibre®), cosmetic ingredients (CosmoCel™ under ECOCERT/COSMOS certification), and consulting-based O&M services for large Indian industrial operators including GACL, OPAL, Aditya Birla, Adani, GNFC, NPCIL, and GAIL.

The company is currently navigating a major operational and reputational shock: a June 30, 2025 explosion at its Pashamylaram (Hyderabad) unit killed 54 workers — the deadliest incident in India's pharmaceutical sector — leading to a 90-day production suspension, culpable homicide proceedings, and the December 2025 arrest of CEO Amit Raj Sinha (granted bail by the Telangana High Court in February 2026). FY26 revenue declined 2.13% to Rs 477.83 crore and Q1 FY27 fell 5.4% YoY, while the company has simultaneously announced a Rs 1.5 billion Gujarat expansion, a Cystic Fibrosis API pipeline (Vanzacaftor, Tezacaftor, Deutivacaftor) targeting Rs 250 crore/year from Q4 FY27 with Vanzacaftor patent protection to 2039, and an August 2026 preferential issue of equity or convertible securities.

Short descriptiontext

Sigachi Industries Limited, founded 1989 in Hyderabad and listed since 2021, manufactures microcrystalline cellulose excipients, APIs, food/nutrition and cosmetic ingredients for global pharmaceutical and industrial buyers, with a parallel O&M services business for large Indian chemical and energy operators.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical excipients, microcrystalline cellulose, active pharmaceutical ingredients, tablet formulation ingredients, pharmaceutical manufacturing
Industry3 codes
PRIMARYIMAMALAD
Nanocellulose & Cellulose Derivatives (CNC/CNF, MCC, ethers/esters)
SECONDARYHLAGAGAI
Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYEUAAAIAD
Bio-based Materials & Fibers (e.g., cellulose derivatives, lignin-based materials, nanocellulose)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
NAICS code3 codes
  • Chemical Manufacturing325
  • Pharmaceutical and Medicine Manufacturing3254
  • Food Manufacturing311
SIC code3 codes
  • Industrial Organic Chemicals2860
  • Plastic Material, Synth Resin/Rubber, Cellulos (No Glass)2820
  • Chemicals & Allied Products2800
Product category
Pharmaceutical Excipients & Ingredients
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Pharmaceutical Excipients
TypeOne Time License
Description

Primary revenue driver including Microcrystalline Cellulose (MCC), pre-formulated excipients, high functionality excipients, thickeners, stabilizers, film coatings, binders, lubricants, carriers, and superdisintegrants for pharmaceutical tablet manufacturing

sigachi.com
2Active Pharmaceutical Ingredients (API)
TypeOne Time License
Description

Revenue contribution doubled to 15% following Trimax Bio Sciences acquisition; includes 9 API products and intermediates for anti-ulcers, antivirals, cardiovascular, and other therapeutic categories

scanx.trade
3Food & Nutrition Products
TypeOne Time License
Description

Ready-to-use additives, stabilisers, dietary fibre products for food processing industry including Joymix brand premixes

sigachi.com
4Cosmetic Ingredients
TypeOne Time License
Description

CosmoCel product line for skincare, haircare, and toiletry applications with ECOCERT/COSMOS certification

sigachi.com
5Operations & Maintenance Services
TypeProfessional Services
Description

Consulting-based O&M services for chemical, petrochemical, pharmaceutical, fertilizer plants, and solar PV operations across India

sigachi.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1B2B pharmaceutical excipients and API products sold through direct sales and channel partnerships
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available - transactions handled through sales team with quote-based pricing for pharmaceutical companies

sigachi.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 13 records shown
1BARETab
Description

Pre-formulated co-processed excipient brand for continuous tablet manufacturing, including BARETab PH, BARETab ODT, and BARETab Nutra variants.

sigachi.com
+12 more records
Core offering1 text field

Sigachi Industries manufactures and supplies microcrystalline cellulose (MCC) and a broad portfolio of pharmaceutical excipients — including binders, superdisintegrants, lubricants, carriers, film coatings, polymer blends, and pre-formulated co-processed excipients — alongside active pharmaceutical ingredients (APIs), food/nutrition premixes, cosmetic cellulose ingredients, and operations & maintenance services for industrial plants.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 60% of products exported to highly regulated markets
+2 more records
Product overview1 text field

Sigachi Industries is a diversified pharmaceutical excipients and ingredients company with a portfolio spanning Active Pharmaceutical Ingredients (APIs), Microcrystalline Cellulose (MCC) products, co-processed excipients, film coatings, and food/nutrition additives. The core products include HiCel™ and AceCel® MCC brands available in multiple grades for various manufacturing processes, complemented by specialized excipients like BARETab® (pre-formulated), HiCel™ HFS/CE15/MCG/SMCC (high functionality), and UltraMod™ SR (sustained release polymers). The PureCoat® film coating line and API portfolio (9 products including Metformin, Atorvastatin, Pregabalin) round out the pharmaceutical offerings, while food products include Joymix® premixes and AceFibre®, and cosmetic ingredients include CosmoCel™. The company also provides Operations & Maintenance services for industrial clients.

Product and service18 records
1Active Pharmaceutical Ingredients (APIs)
CategoryActive Pharmaceutical Ingredients
2HiCel™ Microcrystalline Cellulose (MCC)
CategoryPharmaceutical Binders
3AceCel® Microcrystalline Cellulose
CategoryPharmaceutical Binders
4BARETab® Pre-Formulated Co-Processed Excipients
CategoryPre-Formulated Excipients
5PureCoat® Film Coating Systems
CategoryFilm Coatings
6UltraMod™ SR Polymer Blends
CategorySustained Release Polymers
7Stargel® Superdisintegrant
CategorySuperdisintegrants
8HiLose™ Superdisintegrant
CategorySuperdisintegrants
9MagLub® Lubricant
CategoryPharmaceutical Lubricants
10FloLub™ Lubricant
CategoryPharmaceutical Lubricants
11Puretalc™ Pharmaceutical Carrier
CategoryPharmaceutical Carriers
12HiCel™ MCC Spheres
CategoryPharmaceutical Carriers
13Joymix® Food Premixes
CategoryFood & Nutrition Premixes
14AceFibre® Dietary Fibre
CategoryDietary Fibre Ingredients
15CosmoCel™ Cosmetic Ingredients
CategoryCosmetic Ingredients
16GloCel® Welding Cellulose
CategoryChemical Industry Cellulose
17CoatCel® Filter Aid Cellulose
CategoryChemical Industry Cellulose
18Operations and Maintenance (O&M) Services
CategoryIndustrial Services
Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Indian Navy
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-03-13
Description

MOU signed for collaboration with Indian Navy, announced in March 2025, representing strategic engagement in government/defense sector.

sigachi.com
2JV Formation
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-10-19
Description

Announcement of joint venture formation in October 2023, expanding strategic partnerships and market reach.

sigachi.com
3Trimax Bio Sciences Private Limited
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-10
Description

Sigachi acquired 80% stake in Trimax Bio Sciences for Rs 100 crore (INR 1 billion) in August 2023, with call option to purchase remaining 20% after three years for up to Rs 25 crore. Trimax is a USFDA, EMEA, and WHO-GMP certified API manufacturer expanding Sigachi's capabilities in pharmaceutical ingredients. Located in Raichur, Karnataka.

thehindubusinessline.com
4NIPER (National Institute of Pharmaceutical Education and Research)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2021-12-15
Description

MOU signed for research and development collaboration with NIPER, India's premier pharmaceutical research institute, announced December 2021.

sigachi.com
5Sigachi US Inc.
Strategic tierCoreTypeOthers
Description

Wholly-owned subsidiary established in the Americas region for sales, marketing, and customer support operations. Located at Monroe Township, New Jersey, USA.

sigachi.com
6Sigachi MENA FZCO
Strategic tierCoreTypeOthers
Description

Wholly-owned subsidiary for Middle East and North Africa market operations. Located in Dubai Silicon Oasis, UAE.

sigachi.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

French specialty starch and polyol producer with pharmaceutical excipient portfolio including MCC and pre-formulated platforms. Comparable supplier to global pharma formulators and overlapping in binders, fillers, and co-processed excipients.

TypeDirect peer
Description

Dutch-headquartered excipient supplier offering MCC, superdisintegrants, and specialty excipients for solid oral dosage forms. Direct competitor to Sigachi in regulated pharma excipient markets across Europe and globally.

TypeBroad incumbent
Description

Global chemical giant with pharmaceutical excipients and API portfolio across binders, disintegrants, and coatings. Broader incumbent offering overlapping products within a much wider specialty chemicals portfolio rather than specializing in cellulose excipients.

4Asahi Kasei
TypeDirect peer
Description

Japanese chemical manufacturer selling Ceolus® brand MCC, a leading specialty cellulose for direct compression. Comparable in product technology and target customers for high-functionality excipients.

TypeBroad incumbent
Description

German specialty chemicals company with pharmaceutical polymers, API, and excipient operations. Broad incumbent in regulated excipient space with overlapping capabilities though not focused on cellulose derivatives.

TypeDirect peer
Description

German-headquartered global leader in MCC and cellulose-based pharmaceutical excipients with the VIVAPUR® and EMCOCEL® brands. Closest direct competitor to Sigachi's HiCel™ MCC portfolio in tablet binder applications.

TypeDirect peer
Description

US-based leader in film coating systems and modified-release excipients. Directly competes with Sigachi's PureCoat® film coating and UltraMod™ polymer blend product categories for oral solid dose formulators.

TypeDirect peer
Description

Taiwanese MCC and cellulose derivative manufacturer serving pharmaceutical and food customers globally. Direct competitor in commodity and specialty MCC grades, particularly across Asian regulated markets.

9Anhui Sunhere Pharmaceutical Excipients
TypeDirect peer
Description

Chinese manufacturer of pharmaceutical excipients including MCC, starch derivatives, and superdisintegrants. Comparable Asian cost-competitive peer targeting similar formulation customers as Sigachi.

10DuPont/MFC (now IFF)
TypeDirect peer
Description

Former FMC BioPolymer business now under IFF, producing MCC under brands such as Avicel®. Direct competitor in pharmaceutical-grade MCC across global regulated markets, overlapping with Sigachi's core product line.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance16 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sigachi

Pharmaceutical Excipients & Ingredientssigachi.com

Sigachi Industries Limited, founded 1989 in Hyderabad and listed since 2021, manufactures microcrystalline cellulose excipients, APIs, food/nutrition and cosmetic ingredients for global pharmaceutical and industrial buyers, with a parallel O&M services business for large Indian chemical and energy operators.

What Sigachi does

Sigachi Industries Limited, founded in 1989 in Hyderabad and publicly listed on BSE/NSE since 2021 (ticker: SIGACHI), is a vertically integrated Indian manufacturer of pharmaceutical excipients, Active Pharmaceutical Ingredients (APIs), food and nutrition additives, and cosmetic ingredients, with a parallel Operations & Maintenance (O&M) services line for chemical, petrochemical, fertilizer, and energy plants. Its core technical platform centres on Microcrystalline Cellulose (MCC) manufacturing — branded as HiCel™ (spray-dried directly compressible grades) and AceCel® (non-spray-dried grades for wet granulation) — extended into co-processed excipients (BARETab® PH/ODT/Nutra, HiCel™ HFS/CE15/SMCC), ready-mix film coatings (PureCoat®), sustained-release polymer blends (UltraMod™ SR), superdisintegrants (Stargel®, HiLose™), and lubricants (MagLub®, FloLub™). Two DSIR-accredited R&D centres support new molecule development, and the company runs five manufacturing facilities across Telangana, Gujarat, and Karnataka with combined capacity of 21,700 MTPA.

The business model is sales-led B2B, selling through direct enterprise sales teams in India, wholly-owned subsidiaries Sigachi US Inc. and Sigachi MENA FZCO in the Americas and Middle East, and channel partners across 65+ countries; approximately 60% of output is exported into highly regulated markets (US, Europe, Australia) where USFDA, EDQM CEP, EXCiPACT GMP, WHO-GMP, HACCP, ISO 9001/14001/45001 certifications act as entry barriers. Pricing is quote-based and negotiated under multi-year contracts. Revenue is generated across four streams: pharmaceutical excipients (the core, including binders, disintegrants, coatings, lubricants, carriers), APIs (9 products including Pregabalin, Ritonavir, Metformin, Atorvastatin — 15% of revenue after the August 2023 acquisition of 80% of Trimax Bio Sciences for Rs 100 crore), food/nutrition premixes (Joymix®, AceFibre®), cosmetic ingredients (CosmoCel™ under ECOCERT/COSMOS certification), and consulting-based O&M services for large Indian industrial operators including GACL, OPAL, Aditya Birla, Adani, GNFC, NPCIL, and GAIL.

The company is currently navigating a major operational and reputational shock: a June 30, 2025 explosion at its Pashamylaram (Hyderabad) unit killed 54 workers — the deadliest incident in India's pharmaceutical sector — leading to a 90-day production suspension, culpable homicide proceedings, and the December 2025 arrest of CEO Amit Raj Sinha (granted bail by the Telangana High Court in February 2026). FY26 revenue declined 2.13% to Rs 477.83 crore and Q1 FY27 fell 5.4% YoY, while the company has simultaneously announced a Rs 1.5 billion Gujarat expansion, a Cystic Fibrosis API pipeline (Vanzacaftor, Tezacaftor, Deutivacaftor) targeting Rs 250 crore/year from Q4 FY27 with Vanzacaftor patent protection to 2039, and an August 2026 preferential issue of equity or convertible securities.

Sigachi firmographics

Firmographics
Name
Sigachi
Legal name
Sigachi Industries Limited
Website
https://sigachi.com
Company type
Public
Founded year
1989
Operating status
Operating
Headcount range
251–500 employees
Short description
Sigachi Industries Limited, founded 1989 in Hyderabad and listed since 2021, manufactures microcrystalline cellulose excipients, APIs, food/nutrition and cosmetic ingredients for global pharmaceutical and industrial buyers, with a parallel O&M services business for large Indian chemical and energy operators.
Ownership category
akta.pro rank

Sigachi industry classification

Industry
Product category
Pharmaceutical Excipients & Ingredients
NAICS
Chemical Manufacturing (325), Pharmaceutical and Medicine Manufacturing (3254), Food Manufacturing (311)
SIC
Industrial Organic Chemicals (2860), Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) (2820), Chemicals & Allied Products (2800)
akta.pro industry
PRIMARYIMAMALAD
Nanocellulose & Cellulose Derivatives (CNC/CNF, MCC, ethers/esters)
SECONDARYHLAGAGAI
Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYEUAAAIAD
Bio-based Materials & Fibers (e.g., cellulose derivatives, lignin-based materials, nanocellulose)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)

Keywords

  • Pharmaceutical excipients
  • Microcrystalline cellulose
  • Active pharmaceutical ingredients
  • Tablet formulation ingredients
  • Pharmaceutical manufacturing

Where Sigachi is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices7 records

Markets served

Sigachi business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Excipients: Primary revenue driver including Microcrystalline Cellulose (MCC), pre-formulated excipients, high functionality excipients, thickeners, stabilizers, film coatings, binders, lubricants, carriers, and superdisintegrants for pharmaceutical tablet manufacturing
  2. Active Pharmaceutical Ingredients (API): Revenue contribution doubled to 15% following Trimax Bio Sciences acquisition; includes 9 API products and intermediates for anti-ulcers, antivirals, cardiovascular, and other therapeutic categories
  3. Food & Nutrition Products: Ready-to-use additives, stabilisers, dietary fibre products for food processing industry including Joymix brand premixes
  4. Cosmetic Ingredients: CosmoCel product line for skincare, haircare, and toiletry applications with ECOCERT/COSMOS certification
  5. Operations & Maintenance Services: Consulting-based O&M services for chemical, petrochemical, pharmaceutical, fertilizer plants, and solar PV operations across India

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B pharmaceutical excipients and API products sold through direct sales and channel partnerships

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Sigachi product offering

Product offering

Core offering

Sigachi Industries manufactures and supplies microcrystalline cellulose (MCC) and a broad portfolio of pharmaceutical excipients — including binders, superdisintegrants, lubricants, carriers, film coatings, polymer blends, and pre-formulated co-processed excipients — alongside active pharmaceutical ingredients (APIs), food/nutrition premixes, cosmetic cellulose ingredients, and operations & maintenance services for industrial plants.

Product overview

Sigachi Industries is a diversified pharmaceutical excipients and ingredients company with a portfolio spanning Active Pharmaceutical Ingredients (APIs), Microcrystalline Cellulose (MCC) products, co-processed excipients, film coatings, and food/nutrition additives. The core products include HiCel™ and AceCel® MCC brands available in multiple grades for various manufacturing processes, complemented by specialized excipients like BARETab® (pre-formulated), HiCel™ HFS/CE15/MCG/SMCC (high functionality), and UltraMod™ SR (sustained release polymers). The PureCoat® film coating line and API portfolio (9 products including Metformin, Atorvastatin, Pregabalin) round out the pharmaceutical offerings, while food products include Joymix® premixes and AceFibre®, and cosmetic ingredients include CosmoCel™. The company also provides Operations & Maintenance services for industrial clients.

Differentiator

Problem solved

Functional benefit

Brands

  • BARETab: Pre-formulated co-processed excipient brand for continuous tablet manufacturing, including BARETab PH, BARETab ODT, and BARETab Nutra variants.
  • HiCel
  • AceCel
  • PureCoat
  • UltraMod
  • MagLub
  • FloLub
  • Joymix
  • CosmoCel
  • GloCel
  • CoatCel
  • Stargel
  • HiLose

Products and services

  • Active Pharmaceutical Ingredients (APIs)
  • HiCel™ Microcrystalline Cellulose (MCC)
  • AceCel® Microcrystalline Cellulose
  • BARETab® Pre-Formulated Co-Processed Excipients
  • PureCoat® Film Coating Systems
  • UltraMod™ SR Polymer Blends
  • Stargel® Superdisintegrant
  • HiLose™ Superdisintegrant
  • MagLub® Lubricant
  • FloLub™ Lubricant
  • Puretalc™ Pharmaceutical Carrier
  • HiCel™ MCC Spheres
  • Joymix® Food Premixes
  • AceFibre® Dietary Fibre
  • CosmoCel™ Cosmetic Ingredients
  • GloCel® Welding Cellulose
  • CoatCel® Filter Aid Cellulose
  • Operations and Maintenance (O&M) Services

Quantifiable outcome

  • 60% of products exported to highly regulated markets
  • +2 more outcomes

Companies that use Sigachi

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Sigachi technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Sigachi partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered strategic and core.

  • Indian NavystrategicStrategic or Co-development Partner · 13 March 2025MOU signed for collaboration with Indian Navy, announced in March 2025, representing strategic engagement in government/defense sector.
  • JV FormationstrategicStrategic or Co-development Partner · 19 October 2023Announcement of joint venture formation in October 2023, expanding strategic partnerships and market reach.
  • Trimax Bio Sciences Private LimitedcoreStrategic or Co-development Partner · 10 August 2023Sigachi acquired 80% stake in Trimax Bio Sciences for Rs 100 crore (INR 1 billion) in August 2023, with call option to purchase remaining 20% after three years for up to Rs 25 crore. Trimax is a USFDA, EMEA, and WHO-GMP certified API manufacturer expanding Sigachi's capabilities in pharmaceutical ingredients. Located in Raichur, Karnataka.
  • NIPER (National Institute of Pharmaceutical Education and Research)strategicStrategic or Co-development Partner · 15 December 2021MOU signed for research and development collaboration with NIPER, India's premier pharmaceutical research institute, announced December 2021.
  • Sigachi US Inc.coreOthersWholly-owned subsidiary established in the Americas region for sales, marketing, and customer support operations. Located at Monroe Township, New Jersey, USA.
  • Sigachi MENA FZCOcoreOthersWholly-owned subsidiary for Middle East and North Africa market operations. Located in Dubai Silicon Oasis, UAE.

Scale indicators15 records

Recent moves10 records

Expansion highlights5 records

Sigachi competitors and assessment

Company assessment

Direct peers

  • Roquette: French specialty starch and polyol producer with pharmaceutical excipient portfolio including MCC and pre-formulated platforms. Comparable supplier to global pharma formulators and overlapping in binders, fillers, and co-processed excipients.
  • DFE Pharma: Dutch-headquartered excipient supplier offering MCC, superdisintegrants, and specialty excipients for solid oral dosage forms. Direct competitor to Sigachi in regulated pharma excipient markets across Europe and globally.
  • Asahi Kasei: Japanese chemical manufacturer selling Ceolus® brand MCC, a leading specialty cellulose for direct compression. Comparable in product technology and target customers for high-functionality excipients.
  • JRS Pharma (J. Rettenmaier & Söhne): German-headquartered global leader in MCC and cellulose-based pharmaceutical excipients with the VIVAPUR® and EMCOCEL® brands. Closest direct competitor to Sigachi's HiCel™ MCC portfolio in tablet binder applications.
  • Colorcon: US-based leader in film coating systems and modified-release excipients. Directly competes with Sigachi's PureCoat® film coating and UltraMod™ polymer blend product categories for oral solid dose formulators.
  • Mingtai Chemical: Taiwanese MCC and cellulose derivative manufacturer serving pharmaceutical and food customers globally. Direct competitor in commodity and specialty MCC grades, particularly across Asian regulated markets.
  • Anhui Sunhere Pharmaceutical Excipients: Chinese manufacturer of pharmaceutical excipients including MCC, starch derivatives, and superdisintegrants. Comparable Asian cost-competitive peer targeting similar formulation customers as Sigachi.
  • DuPont/MFC (now IFF): Former FMC BioPolymer business now under IFF, producing MCC under brands such as Avicel®. Direct competitor in pharmaceutical-grade MCC across global regulated markets, overlapping with Sigachi's core product line.

Broad incumbents

  • BASF: Global chemical giant with pharmaceutical excipients and API portfolio across binders, disintegrants, and coatings. Broader incumbent offering overlapping products within a much wider specialty chemicals portfolio rather than specializing in cellulose excipients.
  • Evonik: German specialty chemicals company with pharmaceutical polymers, API, and excipient operations. Broad incumbent in regulated excipient space with overlapping capabilities though not focused on cellulose derivatives.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Sigachi social profiles

Digital presence

Sigachi compliance and trust

Trust signal

Compliance16 records

Sigachi financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sigachi leadership team

Management profile

Number of profiles

Profiles10 records

Sigachi subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Sigachi funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sigachi M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sigachi

What does Sigachi do?

Sigachi Industries manufactures and supplies microcrystalline cellulose (MCC) and a broad portfolio of pharmaceutical excipients — including binders, superdisintegrants, lubricants, carriers, film coatings, polymer blends, and pre-formulated co-processed excipients — alongside active pharmaceutical ingredients (APIs), food/nutrition premixes, cosmetic cellulose ingredients, and operations & maintenance services for industrial plants.

Is Sigachi a public or private company?

Sigachi is a public company. It is classified as public and is currently operating.

When was Sigachi founded?

Sigachi was founded in 1989. It employs 251 to 500 people.

Where is Sigachi based?

Sigachi is headquartered in Hyderabad, India, in the Asia region.

How does Sigachi make money?

Five revenue lines are on record. Pharmaceutical Excipients are the primary driver. The others are active Pharmaceutical Ingredients (API), food & Nutrition Products, cosmetic Ingredients and operations & Maintenance Services.

Who are Sigachi's main competitors?

Direct peers on record are Roquette, DFE Pharma, Asahi Kasei, JRS Pharma (J. Rettenmaier & Söhne), Colorcon, Mingtai Chemical, Anhui Sunhere Pharmaceutical Excipients and DuPont/MFC (now IFF). Broad incumbents are BASF and Evonik.

Does Sigachi have an API?

No public API is recorded for Sigachi.

What industry is Sigachi in?

Sigachi's product category is Pharmaceutical Excipients & Ingredients. Its primary akta.pro industry code is IMAMALAD, Nanocellulose & Cellulose Derivatives (CNC/CNF, MCC, ethers/esters), with a secondary code of HLAGAGAI, Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines). Its NAICS code is 325 and its SIC code is 2860.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScanXSigachi Industries AGM approves ₹0.10 per share dividend for FY26Sigachi Industries shareholders approved a ₹0.10 per share dividend for FY26 at its AGM on September 29, 2026. The meeting also reappointed the executive vice chairman and two independent directors, and approved a material related party transaction with Trimax Bio Sciences. A resolution was passed on the deviation in IPO object utilization.ScanXSigachi Industries reports 11.2% energy drop in FY26 sustainability filingSigachi Industries reported an 11.2% drop in total energy consumption to 3,60,165.60 GJ in FY26, with Scope 2 emissions falling 18.4% and Scope 3 emissions measured for the first time at 93,118.53 tCO2e. Energy intensity per output rose sharply to 35.84 GJ/MT, and safety reforms followed a Pashamylaram incident.ScanXSigachi Industries holds EGM to approve warrant issue and capital hikeSigachi Industries held its EGM on September 15, 2026, to approve a preferential issue of up to 11 crore convertible warrants and an increase in authorized share capital. Fifty-eight members attended via video conference, satisfying quorum. The voting results will be disseminated to exchanges and posted on the company's website.Business StandardSigachi Industries Ltd leads losers in 'B' groupSigachi Industries Ltd fell 15.96% to Rs 31.86 on 15 September 2026, leading the BSE's 'B' group. Other losers included Baid Finserv, SMS Pharmaceuticals, VTM, and IL&FS Investment Managers, with trading volumes exceeding monthly averages.The Times of India15 mainboard IPOs doubled investor money on listing day in last 6 years. See full list - IPO JackpotIndia's mainboard IPO market ended a 609-day dry spell of listing-day gains above 100%, with 15 stocks doubling investors' money on debut. The list includes Vibhor Steel Tubes at an 181.5% premium, Sigachi Industries at 253%, and Tata Technologies at 140%.ScanXSigachi Industries board to consider preferential issue on August 22Sigachi Industries Limited has scheduled a board meeting for August 22, 2026, to consider a preferential issue of equity or convertible securities to raise capital from promoters and non-promoters. The company announced this move alongside its Q1 FY26 financial results, which showed a return to profitability with a consolidated net profit of ₹814.47 lakh despite a decline in revenue.ScanXSigachi Industries Q1FY27 PAT up 8% QoQ to ₹82 millionSigachi Industries reported a consolidated net profit of ₹82 million for Q1FY27, an 8% increase quarter-on-quarter, driven by reduced finance costs and the absence of exceptional items that caused a significant loss in the prior year. Despite this bottom-line improvement, the company's EBITDA fell 31.5% year-on-year to ₹165 million as revenue contracted by 5.4% to ₹1,213 million. The Active Pharmaceutical Ingredients (API) segment saw its contribution to revenue double to 15%, while Microcrystalline Cellulose (MCC) remained the primary revenue driver at 68%.Business StandardSigachi Laboratories standalone net profit rises 0.92% in the June 2026 quarterSigachi Laboratories reported a 0.92% increase in standalone net profit to Rs 1.10 crore for the quarter ended June 2026, compared to Rs 1.09 crore in the same quarter of the previous year. Sales grew 9.38% year-on-year to Rs 1.40 crore in the June 2026 quarter. The article is a routine quarterly earnings announcement with small absolute financial figures.The HinduSigachi industries blast should serve as a wake up call: Telangana Labour Minister VivekTelangana Labour Minister G. Vivek Venkatswamy addressed a national workshop on process safety of combustible dusts, citing the Sigachi Industries blast in June 2025 as a wake-up call for industries that failed to invest even ₹15 lakh in safety measures, resulting in loss of lives and financial losses. The Minister called for industries to adopt comprehensive safety protocols and warned that attempts to save costs on safety infrastructure often lead to devastating human and financial consequences. He directed the Factories Department to frame regulations within six months to ensure hazardous operations are handled only by permanent employees and not contract workers.The Times of IndiaYear on, Sigachi relief stalled, lives in strain | Hyderabad News - The Times of IndiaOne year after an explosion at Sigachi Industries' Pashamylaram unit killed 54 workers and injured 20, families say they are still awaiting full compensation promised by the government and the company. Families have received only about Rs 42 lakh so far against the announced Rs 1 crore per deceased package, with most victims being migrants from Bihar, Odisha, Uttar Pradesh and Andhra Pradesh. Civil society groups and victims' families held a rally demanding immediate release of pending compensation and accountability beyond just the CEO's arrest.